Live Breaking News & Updates on Director Nimish|Page 3

Stay updated with breaking news from Director nimish. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Rating of "Buy" from Analysts

Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has been assigned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the […] ....

Stifel Nicolaus , Nimishp Shah , Apogee Therapeutics Company Profile , Securities Exchange Commission , Apogee Therapeutics Inc , Jefferies Financial Group , Apogee Therapeutics , Get Free Report , Marketbeat Ratings , Financial Group , Director Nimish , Exchange Commission , Therapeutics Trading Down , Get Free , Apogee Therapeutics Daily , Nasdaq Apge ,

Apogee Therapeutics, Inc.'s (NASDAQ:APGE) Quiet Period Will End on August 23rd

Apogee Therapeutics, Inc.'s (NASDAQ:APGE) Quiet Period Will End on August 23rd
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Nimishp Shah , Stifel Nicolaus , Apogee Therapeutics Inc , Jefferies Financial Group , Securities Exchange Commission , Exchange Commission , Apogee Therapeutic , Get Free Report , Apogee Therapeutics , Financial Group , Director Nimish , Apogee Therapeutics Daily ,

Apogee Therapeutics (NASDAQ:APGE) Reaches New 12-Month High at $23.16

Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) shares reached a new 52-week high on Wednesday . The company traded as high as $23.16 and last traded at $23.07, with a volume of 138737 shares traded. The stock had previously closed at $22.22. Wall Street Analyst Weigh In APGE has been the subject of a […] ....

Stifel Nicolaus , Nimishp Shah , Securities Exchange Commission , Jefferies Financial Group , Apogee Therapeutics Inc , Apogee Therapeutics , Get Free Report , Financial Group , Director Nimish , Exchange Commission , Apogee Therapeutics Daily , Nasdaq Apge ,

Research Analysts' Recent Ratings Updates for Apogee Therapeutics (APGE)

Several brokerages have updated their recommendations and price targets on shares of Apogee Therapeutics (NASDAQ: APGE) in the last few weeks: 8/8/2023 – Apogee Therapeutics is now covered by analysts at TD Cowen. They set an “outperform” rating on the stock. 8/8/2023 – Apogee Therapeutics is now covered by analysts at Wedbush. They set an […] ....

Nimishp Shah , Stifel Nicolaus , News Ratings For Apogee Therapeutics Inc Daily , Apogee Therapeutics Inc , Jefferies Financial Group Inc , Securities Exchange Commission , Apogee Therapeutics , Director Nimish , Exchange Commission , Apogee Therapeutics Inc Daily , Nasdaq Apge ,

Apogee Therapeutics (NASDAQ:APGE) Now Covered by TD Cowen

TD Cowen initiated coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock. APGE has been the topic of several other research reports. Guggenheim began coverage on shares of Apogee Therapeutics in a research report on […] ....

Stifel Nicolaus , Nimishp Shah , Apogee Therapeutics Company Profile , Apogee Therapeutics Inc , Jefferies Financial Group , Apogee Therapeutics , Free Report , Director Nimish , Get Free Report , Apogee Therapeutics Daily , Nasdaq Apge , Initiated Coverage , Td Cowen ,